The development of in vitro seed amplification assays (SAA) detecting misfolded alpha-
synuclein (αSyn) in cerebrospinal fluid (CSF) and other tissues has provided a pathology …

The alpha-synuclein (aSyn) seed amplification assay (SAA) can identify aSyn aggregates as
indicator for Lewy body pathology in biomaterials of living patients and help in diagnosing …

Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein
(αSyn) RT-QuIC has emerged as a promising assay to detect misfolded αSyn in clinically or …

Recent studies have been able to detect α-synuclein (αSyn) seeding in formaldehyde-fixed
paraffin-embedded (FFPE) tissues from patients with synucleinopathies using seed …

Objective The purpose of this study was to determine the sensitivity and specificity of α‐
synuclein seed amplification assay (αSyn‐SAA) in antemortem and postmortem …

Definitive diagnosis of Parkinson's disease (PD) and dementia with Lewy bodies (DLB)
relies on postmortem finding of disease-associated alpha-synuclein (αSyn D) as misfolded …

The clinical diagnosis of synucleinopathies, including Parkinson's disease (PD), dementia
with Lewy bodies (DLB), and multiple system atrophy (MSA), is challenging, especially at an …

Lewy body dementia encompasses the common neurodegenerative disorders Dementia
with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Lewy Body disease …

Background α-Synuclein is a small soluble protein, whose physiological function in the
healthy brain is poorly understood. Intracellular inclusions of α-synuclein, referred to as …

The clinicopathological heterogeneity in Lewy-body diseases (LBD) highlights the need for
pathology-driven biomarkers in-vivo. Misfolded alpha-synuclein (α-Syn) is a lead candidate …